Several studies reported that the abnormal expression and activation of ERBB4 could lead to human cancers (Hynes and Lane, 2005; Qiu et al., 2008; Segers et al., 2020) and the loss of function due to mutations also associated with autosomal-dominant ALS (Takahashi et al., 2013). This evidence concerns the gene ERBB4 and cancer.